Suxethonium is a depolarising muscle relaxant, with low incidence of postoperative muscle pain.

Batanopride, previously known as BMY-25801, a 5-hydroxytryptamine 3 receptor antagonist, was studied against emesis for cancer patients that were treated by chemotherapy procedure. Batanopride had the dose-limiting side effects including hypotension and long QT syndrome that is why any further experiments for its medical application were discontinued.

Clobenetine is benzomorphan derivative developed by Boehringer-Ingelheim. Clobenetine acts as a sodium channel blocker and displaces radioligand from neurotoxin receptor site 2 of the Na(+) channel in rat brain synaptosomes with IC50 of 49 nM. The IC50 value for the inactivated Na(+) channels was much lower than for Na(+) channels in the resting state. In animal models, clobenetine reduced lesion size in mice and rats when administered 5 min after permanent focal cerebral ischemia at doses that did not impair motor coordination. Clobenetine produced significant analgesic and anti-hyperalgesic effects in the rat model of arthritis, induced by complete Freund's adjuvant. In the early 2000s, the compound was investigated in phase II clinical trial for the treatment of thromboembolic stroke, but no results were reported.

Capravirine (S-1153, AG1549) is a 1,2,4,5-tetrasubstituted imidazole derivative patented by pharmaceutical company Shionogi as specific inhibitors of HIV-​1 reverse transcriptase. However, safety and efficacy studies showed that Capravirine had no specific advantages over currently used NNRTIs. Consequently, clinical trials were discontinued after phase IIb.